Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Hoenigl, Martin ; Jain, Sonia ; Moore, David ; Collins, Deborah ; Sun, Xiaoying ; Anderson, Peter L. ; Corado, Katya ; Blumenthal, Jill S. ; Daar, Eric S. ; Milam, Joel ; Dubé, Michael P. ; Morris, Sheldon
• Corporate Authors:
  for the California Collaborative Treatment Group 595 Team
• Description:
  The effectiveness of oral HIV preexposure prophylaxis (PrEP) strongly depends on maintaining adherence. We investigated the association between substance use and PrEP adherence, as well as incident sexually transmitted infections (STIs) in a high-risk cohort of 394 participants (391 men who have sex with men and 3 transgender women) who were enrolled in a PrEP demonstration project. We assessed baseline and ongoing substance use over a 48-week period for stimulants and nonstimulant substances and for each substance separately. We measured PrEP adherence by using dried blood spots to obtain levels of tenofovir diphosphate. No differences in these levels were found between substance users and nonsubstance users. Baseline stimulant use was strongly associated (odds ratio 3.4; p<0.001) with incident STIs during the study. Thus, PrEP adherence was not decreased by substance use. Because substance users had increased rates of STIs, indicating higher-risk behavior, they might be excellent candidates for PrEP.
• Subjects:
  Adherence Adherence To HIV Preexposure Prophylaxis Alcohol CME Dried Blood Spots HIV HIV And Other Retroviruses Injection Drug Use Men Who Have Sex With Men Methamphetamine MSM Persons Who Injected Drugs PrEP Research Sexually Transmitted Infections Substance Use Substance Use And Adherence To HIV Preexposure Prophylaxis For Men Who Have Sex With Men Transgender Women Viruses

  More +
• Source:
  Emerg Infect Dis. 24(12):2292-2302
• Pubmed ID:
  30457536
• Pubmed Central ID:
  PMC6256399
• Document Type:
  Journal Article
• Funding:
  P50 DA026306/DA/NIDA NIH HHS/United States ; K24 AI064086/AI/NIAID NIH HHS/United States ; R25 MH081482/MH/NIMH NIH HHS/United States ; KL2 TR001444/TR/NCATS NIH HHS/United States ; P30 MH062512/MH/NIMH NIH HHS/United States ; P30 AI036214/AI/NIAID NIH HHS/United States ; R01 MH100974/MH/NIMH NIH HHS/United States ; R21 MH113477/MH/NIMH NIH HHS/United States ; R24 AI106039/AI/NIAID NIH HHS/United States
• Volume:
  24
• Issue:
  12
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:9bad944872f10657de0638eda908aa750323ff44a1cac84e8fdbb7ed3f81be20
• Download URL:
  https://stacks.cdc.gov/view/cdc/61345/cdc_61345_DS1.pdf
• File Type:
  [PDF - 1.35 MB ]